spiriva handihaler- tiotropium bromide capsule
boehringer ingelheim pharmaceuticals, inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - tiotropium 18 ug - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was
favynd 18 microgram inhalation powder, capsule
boehringer ingelheim international gmbh - tiotropium bromide monohydrate - inhalation powder, capsule - 18 microgram - anticholinergics
srivasso 18 microgram, inhalation powder, hard capsule
boehringer ingelheim international gmbh - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide
spiriva inhalation capsule 18 mcg with handihaler
boehringer ingelheim singapore pte. ltd. - tiotropium bromide monohydrate eqv tiotropium - capsule - 18 mcg
spiriva handihaler- tiotropium bromide capsule
a-s medication solutions - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was
spiriva 18 microgram inhalation powder, hard capsule
merit pharmaceuticals limited - tiotropium bromide - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide
spiriva 18 mikrogramm hartkapseln mit pulver zur inhalation
spiriva 18 microgram inhalation powder, capsule
b & s healthcare - tiotropium - inhalation powder, capsule - 18 microgram - anticholinergics
spiriva 18 microgram, inhalation powder, hard capsule
imed healthcare ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide
spiriva
boehringer ingelheim pty ltd - tiotropium -